Advanced Heart, Kidney, Metabolic Disease Linked to Higher Cancer Risk

As heart, kidney and metabolic disease advances together, cancer risk rises too, and the danger grows with each stage. In a study published Monday in Circulation: Population Health and Outcomes, researchers found that people with stage 3 cardiovascular-kidney-metabolic, or CKM, syndrome were about 25% more likely to be diagnosed with cancer four years later than those in earlier stages, while stage 4 carried about a 30% higher risk.

The findings matter because CKM syndrome is not rare. The American Heart Association introduced the framework in 2023 to describe linked heart disease, kidney disease and metabolic problems such as obesity and diabetes across stages from no risk factors to established cardiovascular disease. The association says nearly 9 in 10 U.S. adults have at least one component of CKM syndrome, and about one in three have at least three risk factors. That means the question is not whether the syndrome touches American communities, but how deeply it is already embedded in everyday life.

Hidehiro Kaneko, M.D., Ph.D., an associate professor in the department of cardiovascular medicine at the University of Tokyo, led the analysis. His team used a Japanese insurance claims database with health check-up data collected from April 2014 through August 2023 and examined risk for 16 cancers. The study included nearly 1.4 million adults, offering one of the clearest looks yet at how worsening CKM burden tracks with later cancer diagnoses.

The broader public health warning is that these conditions rarely arrive alone. A person living with obesity may later develop diabetes, then kidney dysfunction, then heart disease, and the new study suggests that cumulative pattern may compound cancer danger as well. The American Heart Association says the biggest threats from CKM syndrome remain death and disability from heart disease and stroke, but the syndrome is also tied to kidney failure, dementia, fatty liver disease, obstructive sleep apnea and increased cancer risk.

The evidence builds on earlier work. A JAMA Network Open study of 128,999 adults in the Prostate, Lung, Colorectal and Ovarian Screening Trial found that midlife comorbidities were associated with higher risk of cancer and cancer death. A 2024 JAMA Cardiology study also found that cardiac, renal and metabolic multimorbidity was prevalent and increasing among U.S. adults.

The practical message for patients and clinicians is to stop treating these illnesses as separate silos. People with diabetes, obesity, kidney disease or heart disease need coordinated care that addresses blood pressure, glucose, weight, kidney function and cancer screening together, because the risk picture is no longer confined to one organ system.